The Role of IL-17 in the Pathogenesis and Treatment of Psoriasis

Overview

Journal J Clin Aesthet Dermatol

Date 2017 Apr 26

PMID 28439340

Citations 12

Authors

Joshua A Zeichner

April Armstrong

Affiliations

Soon will be listed here.

Citing Articles

Memory Cells in Infection and Autoimmunity: Mechanisms, Functions, and Therapeutic Implications.

Giri S, Batra L Vaccines (Basel). 2025; 13(2).

PMID: 40006751 PMC: 11860616. DOI: 10.3390/vaccines13020205.

Patient-reported Outcomes and Burden of Disease in Paediatric Patients with Psoriasis: Real-world Data from EU5 and US.

Seyger M, Paller A, Sticherling M, Bachhuber T, Thomas N, Hetherington J Acta Derm Venereol. 2023; 103:adv2544.

PMID: 37073960 PMC: 10128148. DOI: 10.2340/actadv.v103.2544.

Identification immune response genes in psoriasis after treatment with secukinumab.

Wang J, Liu Y, Zhang Y, Wang S, Kang S, Mi N BMC Med Genomics. 2023; 16(1):77.

PMID: 37029373 PMC: 10082531. DOI: 10.1186/s12920-023-01507-w.

Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study.

Foley P, Tsai T, Rodins K, Hamadah I, Ammoury A, Dayem H Dermatol Ther (Heidelb). 2022; 12(2):511-527.

PMID: 35038128 PMC: 8850524. DOI: 10.1007/s13555-021-00675-w.

The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation.

Seddik A, Melzer N, Tsotra F, Ostwald D Pharmacoecon Open. 2021; 6(2):265-275.

PMID: 34668167 PMC: 8864046. DOI: 10.1007/s41669-021-00305-3.

References

Del Rosso J, Levin J . The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin. J Clin Aesthet Dermatol. 2011; 4(9):22-42. PMC: 3175800. View

Goodman W, Cooper K, McCormick T . Regulation generation: the suppressive functions of human regulatory T cells. Crit Rev Immunol. 2012; 32(1):65-79. PMC: 3413266. DOI: 10.1615/critrevimmunol.v32.i1.40. View

de Korte J, Sprangers M, Mombers F, Bos J . Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004; 9(2):140-7. DOI: 10.1046/j.1087-0024.2003.09110.x. View

Tsoi L, Spain S, Knight J, Ellinghaus E, Stuart P, Capon F . Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012; 44(12):1341-8. PMC: 3510312. DOI: 10.1038/ng.2467. View

Piskin G, Sylva-Steenland R, Bos J, Teunissen M . In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006; 176(3):1908-15. DOI: 10.4049/jimmunol.176.3.1908. View

Chiricozzi A, Guttman-Yassky E, Suarez-Farinas M, Nograles K, Tian S, Cardinale I . Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol. 2010; 131(3):677-87. DOI: 10.1038/jid.2010.340. View

Lowes M, Suarez-Farinas M, Krueger J . Immunology of psoriasis. Annu Rev Immunol. 2014; 32:227-55. PMC: 4229247. DOI: 10.1146/annurev-immunol-032713-120225. View

Harder J, Schroder J, Glaser R . The skin surface as antimicrobial barrier: present concepts and future outlooks. Exp Dermatol. 2012; 22(1):1-5. DOI: 10.1111/exd.12046. View

Augustin M, Abeysinghe S, Mallya U, Qureshi A, Roskell N, McBride D . Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial. J Eur Acad Dermatol Venereol. 2015; 30(4):645-9. PMC: 4814339. DOI: 10.1111/jdv.13478. View

10.

Martin D, Towne J, Kricorian G, Klekotka P, Gudjonsson J, Krueger J . The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2012; 133(1):17-26. PMC: 3568997. DOI: 10.1038/jid.2012.194. View

11.

Chang S, Reynolds J, Pappu B, Chen G, Martinez G, Dong C . Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 2011; 35(4):611-21. PMC: 5800502. DOI: 10.1016/j.immuni.2011.09.010. View

12.

Chiricozzi A, Krueger J . IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013; 22(8):993-1005. DOI: 10.1517/13543784.2013.806483. View

13.

Jariwala S . The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res. 2007; 299(8):359-66. PMC: 1978540. DOI: 10.1007/s00403-007-0775-4. View

14.

Blauvelt A, Brown M, Gordon K, Kavanaugh A, Leonardi C, Stockfleth E . Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. J Clin Aesthet Dermatol. 2013; 6(9 Suppl):S2-S20. PMC: 3809592. View

15.

Lowes M, Bowcock A, Krueger J . Pathogenesis and therapy of psoriasis. Nature. 2007; 445(7130):866-73. DOI: 10.1038/nature05663. View

16.

Armstrong A, Schupp C, Wu J, Bebo B . Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. 2013; 7(12):e52935. PMC: 3532407. DOI: 10.1371/journal.pone.0052935. View

17.

Ghadially R, Reed J, Elias P . Stratum corneum structure and function correlates with phenotype in psoriasis. J Invest Dermatol. 1996; 107(4):558-64. DOI: 10.1111/1523-1747.ep12582813. View

18.

Kagami S, Rizzo H, Lee J, Koguchi Y, Blauvelt A . Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol. 2009; 130(5):1373-83. PMC: 2892169. DOI: 10.1038/jid.2009.399. View

19.

Theoharides T, Alysandratos K, Angelidou A, Delivanis D, Sismanopoulos N, Zhang B . Mast cells and inflammation. Biochim Biophys Acta. 2010; 1822(1):21-33. PMC: 3318920. DOI: 10.1016/j.bbadis.2010.12.014. View

20.

Lin A, Rubin C, Khandpur R, Wang J, Riblett M, Yalavarthi S . Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol. 2011; 187(1):490-500. PMC: 3119764. DOI: 10.4049/jimmunol.1100123. View